Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
Sponsor: Innostellar Biotherapeutics Co.,Ltd
Summary
Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.
Official title: A Clinical Trial to Evaluate the Safety and Efficacy of Subretinal Re-Administration of LX101 to the Contralateral Eye in Subjects With Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2023-09-12
Completion Date
2029-03
Last Updated
2025-06-29
Healthy Volunteers
No
Conditions
Interventions
LX101
Subretinal administration of LX101 to the contralateral, previously uninjected eye
Locations (1)
Shanghai General Hospital
Shanghai, Shanghai Municipality, China